MSMP expression regulation in cancer cells and its pro-angiogenic role in ovarian tumors (Homo sapiens)
From WikiPathways
Description
Proposed model for regulation of MSMP expression in cancer cells under hypoxic conditions and the proangiogenic role of MSMP in ovarian tumors.
The recruitment of the transcriptional repressor CTCF to the MSMP enhancer region is regulated by changes in H3 acetylation of the MSMP enhancer. In hypoxic conditions, the repressor-enhancer binding is disrupted, leading to increased expression of MSMP. Secretion of MSMP triggers MAPK signaling in endothelial cells (presumably via CCR2 signaling), which promotes angiogenesis.
This suggests that MSMP inhibition in combination with antiangiogenesis drugs (anti-VEGF) could be a new strategy to overcome resistance to antiangiogenesis therapy.
Description adapted from Mitamura et al.Quality Tags
 | Review changes for Approved |
 | Community: CPTAC |
 |  |
Ontology Terms
Saving...Pathway Ontology : disease pathway
Disease : COVID-19
Cell Type : vascular associated smooth muscle cell
Bibliography
- Mitamura T, Pradeep S, McGuire M, Wu SY, Ma S, Hatakeyama H, Lyons YA, Hisamatsu T, Noh K, Villar-Prados A, Chen X, Ivan C, Rodriguez-Aguayo C, Hu W, Lopez-Berestein G, Coleman RL, Sood AK; ''Induction of anti-VEGF therapy resistance by upregulated expression of microseminoprotein (MSMP).''; Oncogene, 2018 PubMed Europe PMC Scholia
History
View all... |
External references
DataNodes
| View all... |
Name  | Type | Database reference | Comment |
|---|---|---|---|
| Angiogenesis | Pathway | WP1539 (WikiPathways)  | |
| CCR2 | GeneProduct | ENSG00000121807 (Ensembl) | |
| CTCF | GeneProduct | ENSG00000102974 (Ensembl) | |
| Hypoxia | Q105688 (Wikidata) | ||
| MAPK signaling | Pathway | WP382 (WikiPathways) | |
| MSMP | GeneProduct | ENSG00000215183 (Ensembl) |
Annotated Interactions
No annotated interactions
